Cargando cotizaciones...
Previsión
No hay datos de analistas disponibles para esta empresa.
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
WuXi XDC Cayman: major shareholder places shares to raise capital – stock falls
A major shareholder of WuXi XDC Cayman, STA Pharmaceutical Hongkong, placed 53.5 million shares at HK$73.23 each, apparently aiming to raise up to US$500 million. The news came with a substantial discount to the previous close and triggered a price drop of about 2.6% to HK$75.25. There was also profit-taking after WuXi’s strong half-year results. » Más en de.investing.com
WuXi XDC posts first-half profit above RMB 1 billion — shares rise about 15%
WuXi XDC reported H1 2026 revenue of RMB 3.7 billion (+37% year‑on‑year) and an adjusted net profit of over RMB 1 billion. Gross margin improved to 37% and order backlog rose to over USD 2 billion, including around USD 120 million of commercial orders. The stock climbed 14.8% to USD 80.15. Management reaffirmed the full-year guidance (consolidated currency‑adjusted revenue growth ~30%, standalone ≥35%) and highlighted effects from the ramp‑up of the new Singapore site and integration costs related to BioDLink. » Más en de.investing.com
WuXi XDC rises almost 12% after strong H1 results
WuXi XDC reported H1 2026 revenue of RMB 3.701 billion (+37% yoy) and an adjusted net profit attributable to shareholders of about RMB 1.027 billion (+37.4%). Gross margin improved to 37.0% and management cited the integration of BioDlink, the expansion of the global production network (including commercial production in Singapore) and the further development of its own technology platforms as drivers of structural growth. The stock then climbed roughly 12% to HK$78. » Más en de.investing.com
Akari starts GMP production of AKTX-101 in partnership with WuXi XDC
Akari Therapeutics has begun GMP-compliant manufacture of its lead ADC program AKTX-101 in an exclusive partnership with WuXi XDC to supply material for regulatory IND-enabling studies. AKTX-101 uses Akari’s PH1 payload, which modulates RNA splicing, and showed high efficacy versus traditional ADCs in preclinical studies. The company plans first-in-human phase 1 studies in about 12 months (end of 2026/early 2027, pending regulatory clearance), recently raised roughly $5 million in fresh capital, received a NASDAQ notice of non-compliance with the minimum bid price requirement, and appointed an interim CFO. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | junio de 2026 | YoY |
|---|---|---|
| Ingresos | 470,77 M | - |
| Beneficio bruto | 174,42 M | - |
| Beneficio neto | 104,04 M | - |
| EBITDA | 152,19 M | - |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 9706,7 M € |
Número de acciones | 1265,28 M |
Máximo/mínimo de 52 semanas | 9,95 € - 5,06 € |
| Dividendos | No |
Beta | -0,78 |
Ratio P/E | 45,95 |
Ratio PEG | 2,09 |
Ratio P/B | 6,24 |
Ratio P/S | 10,29 |
Perfil de la empresa
WuXi XDC Cayman Inc., una sociedad holding de inversiones, opera como organización de investigación por contrato, desarrollo y fabricación en China, Norteamérica, Europa y a nivel internacional. Se dedica al descubrimiento, la investigación, el desarrollo y la fabricación de conjugados anticuerpo-fármaco, bioconjugados, intermedios de anticuerpos monoclonales y enlazadores-carga útil asociados a bioconjugados. La compañía fue fundada en 2013 y tiene su sede en Wuxi, China. WuXi XDC Cayman Inc. opera como filial de WuXi Biologics (Cayman) Inc.
| Nombre | WuXi XDC Cayman Inc |
| CEO | Jincai Li |
| Sede | Wuxi,
js China |
| Sitio web | |
| Sector | Salud |
| Industria | Herramientas y servicios de ciencias de la vida |
| Salida a bolsa | 18/06/2012 |
| Empleados | 2662 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
Düsseldorf | L74.DU |
Frankfurt | L74.F |
München | L74.MU |